If you had looked at Recursion Pharmaceuticals on the first trading day of 2026, with bullish analysts talking up AI driven drug discovery and bearish voices focused on cash burn and regulatory risk, ...
Source LinkIf you had looked at Recursion Pharmaceuticals on the first trading day of 2026, with bullish analysts talking up AI driven drug discovery and bearish voices focused on cash burn and regulatory risk, ...
Source Link
Comments